Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. more
Time Frame | SPRO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.55% | -2.27% | -0.57% |
1-Month Return | -18.32% | -3.96% | 1.21% |
3-Month Return | -21.9% | -9.7% | 7.57% |
6-Month Return | -21.9% | -3.37% | 11.45% |
1-Year Return | -17.05% | 3.71% | 28.48% |
3-Year Return | -92.16% | 3.8% | 29.52% |
5-Year Return | -90.35% | 39.78% | 90.66% |
10-Year Return | -90.7% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.74M | 9.33M | 18.26M | 48.58M | 96.73M | [{"date":"2019-12-31","value":4.9,"profit":true},{"date":"2020-12-31","value":9.64,"profit":true},{"date":"2021-12-31","value":18.87,"profit":true},{"date":"2022-12-31","value":50.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 65.78M | 67.00M | 1.12M | 1.55M | 367.00K | [{"date":"2019-12-31","value":98.17,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":1.67,"profit":true},{"date":"2022-12-31","value":2.31,"profit":true},{"date":"2023-12-31","value":0.55,"profit":true}] |
Gross Profit | 4.74M | 9.33M | 17.14M | 47.03M | 96.37M | [{"date":"2019-12-31","value":4.92,"profit":true},{"date":"2020-12-31","value":9.68,"profit":true},{"date":"2021-12-31","value":17.78,"profit":true},{"date":"2022-12-31","value":48.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 93.88% | 96.82% | 99.62% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.88,"profit":true},{"date":"2022-12-31","value":96.82,"profit":true},{"date":"2023-12-31","value":99.62,"profit":true}] |
Operating Expenses | 67.96M | 88.44M | 106.23M | 79.15M | 75.25M | [{"date":"2019-12-31","value":63.97,"profit":true},{"date":"2020-12-31","value":83.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.51,"profit":true},{"date":"2023-12-31","value":70.84,"profit":true}] |
Operating Income | (63.22M) | (79.11M) | (87.97M) | (42.20M) | 21.48M | [{"date":"2019-12-31","value":-294.29,"profit":false},{"date":"2020-12-31","value":-368.29,"profit":false},{"date":"2021-12-31","value":-409.53,"profit":false},{"date":"2022-12-31","value":-196.44,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 3.62M | 1.23M | (3.38M) | (5.72M) | 7.86M | [{"date":"2019-12-31","value":46.04,"profit":true},{"date":"2020-12-31","value":15.7,"profit":true},{"date":"2021-12-31","value":-42.99,"profit":false},{"date":"2022-12-31","value":-72.74,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (60.92M) | (78.28M) | (89.76M) | (46.41M) | 25.40M | [{"date":"2019-12-31","value":-239.82,"profit":false},{"date":"2020-12-31","value":-308.14,"profit":false},{"date":"2021-12-31","value":-353.31,"profit":false},{"date":"2022-12-31","value":-182.71,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (750.00K) | (761.00K) | 1.54M | 1.61M | 2.60M | [{"date":"2019-12-31","value":-28.87,"profit":false},{"date":"2020-12-31","value":-29.29,"profit":false},{"date":"2021-12-31","value":59.47,"profit":true},{"date":"2022-12-31","value":62.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (60.17M) | (77.52M) | (91.30M) | (48.03M) | 22.81M | [{"date":"2019-12-31","value":-263.86,"profit":false},{"date":"2020-12-31","value":-339.91,"profit":false},{"date":"2021-12-31","value":-400.34,"profit":false},{"date":"2022-12-31","value":-210.59,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (60.92M) | (78.28M) | (89.76M) | (46.41M) | 22.81M | [{"date":"2019-12-31","value":-267.14,"profit":false},{"date":"2020-12-31","value":-343.24,"profit":false},{"date":"2021-12-31","value":-393.56,"profit":false},{"date":"2022-12-31","value":-203.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (60.17M) | (77.52M) | (91.30M) | (48.03M) | 22.81M | [{"date":"2019-12-31","value":-263.86,"profit":false},{"date":"2020-12-31","value":-339.91,"profit":false},{"date":"2021-12-31","value":-400.34,"profit":false},{"date":"2022-12-31","value":-210.59,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (3.30) | (3.58) | (2.89) | (1.66) | 0.52 | [{"date":"2019-12-31","value":-634.62,"profit":false},{"date":"2020-12-31","value":-688.46,"profit":false},{"date":"2021-12-31","value":-555.77,"profit":false},{"date":"2022-12-31","value":-319.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
SPRO | |
---|---|
Cash Ratio | 1.55 |
Current Ratio | 2.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SPRO | |
---|---|
ROA (LTM) | 10.48% |
ROE (LTM) | 25.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SPRO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SPRO | |
---|---|
Trailing PE | 13.38 |
Forward PE | NM |
P/S (TTM) | 0.49 |
P/B | 0.89 |
Price/FCF | 5 |
EV/R | 0.14 |
EV/Ebitda | 0.75 |
PEG | NM |
Spero Therapeutics Inc (SPRO) share price today is $1.07
Yes, Indians can buy shares of Spero Therapeutics Inc (SPRO) on Vested. To buy Spero Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SPRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Spero Therapeutics Inc (SPRO) via the Vested app. You can start investing in Spero Therapeutics Inc (SPRO) with a minimum investment of $1.
You can invest in shares of Spero Therapeutics Inc (SPRO) via Vested in three simple steps:
The 52-week high price of Spero Therapeutics Inc (SPRO) is $1.89. The 52-week low price of Spero Therapeutics Inc (SPRO) is $1.01.
The price-to-earnings (P/E) ratio of Spero Therapeutics Inc (SPRO) is 13.75
The price-to-book (P/B) ratio of Spero Therapeutics Inc (SPRO) is 0.89
The dividend yield of Spero Therapeutics Inc (SPRO) is 0.00%
The market capitalization of Spero Therapeutics Inc (SPRO) is $62.70M
The stock symbol (or ticker) of Spero Therapeutics Inc is SPRO